Fresenius Covers All Bases With Akorn Acquisition And Merck Biosimilar Buy
Executive Summary
Fresenius is shoring up its near-term US growth prospects by acquiring generics firm Akorn, as well boosting its future outlook by entering the biosimilars space via a deal with Merck KgaA.
You may also be interested in...
Kabi: US Pegfilgrastim Crowd Is An Opportunity For Us, Not A Deterrent
In the second part of Generics Bulletin’s exclusive interview with Fresenius Kabi’s senior vice president for biosimilars in the US, Ali Ahmed, he explains why Kabi is relishing the prospect of competing in pegfilgrastim and what the acquisition of mAbxience means for the company’s prospects and vision.
Are Investors ‘Skeptical’ Of Fresenius Kabi’s €495m mAbxience Acquisition?
Fresenius Kabi’s proposed agreement to acquire a majority 55% stake in biosimilars firm mAbxience has been put under the microscope by one analyst, amid setbacks that have stymied the return on investment for Kabi’s nascent biosimilars unit.
Kabi Brings In Reddy’s Rituximab As Biosimilar Breakeven Date Retreats
The Fresenius group had much to say of Fresenius Kabi’s biosimilar business during the firm’s Q4 and year-end results call, which disclosed a US in-licensing deal for Dr Reddy’s proposed rituximab biosimilar and suggested additional biosimilar manufacturing is among its top priorities.